Medicine House Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Medicine House Pharmaceutical Export Portfolio Dataset — 3 Products, $634.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medicine House — Pharmaceutical Exporter Profile (2026) | 3 Products, $634.5K Trade | TransData Nexus

Product Portfolio — Top 3 by Export Value

Medicine House exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Insulin	Diabetes & Endocrine	$571.4K	17	0.8%	11
2	Ustekinumab	Biologics & Immunotherapy	$36.9K	5	2.9%	9
3	Daunorubicin	Advanced Oncology	$26.1K	3	3.8%	6

Medicine House exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $634.5K. The top category is Diabetes & Endocrine (90.1% of portfolio), followed by Biologics & Immunotherapy (5.8%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Medicine House — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Medicine House is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2021, the company is headquartered in Ahmedabad, Gujarat, India. It operates as a proprietorship under the leadership of Mehulbhai Pravinbhai Vaghela, who serves as the CEO. The company is registered with the Goods and Services Tax (GST) under the number 24ASDPV0995N1Z1. While specific details regarding the Corporate Identification Number (CIN), revenue, and employee count are not publicly disclosed, Medicine House is known for its commitment to providing high-quality pharmaceutical products.

2Manufacturing Facilities

Medicine House operates manufacturing facilities in Ahmedabad, Gujarat, India. These plants are equipped to produce a range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company emphasizes quality control and adheres to Good Manufacturing Practices (GMP) to ensure the safety and efficacy of its products. Specific details regarding production capacities and specialized manufacturing capabilities are not publicly available.

3Key Leadership

The leadership of Medicine House is headed by CEO Mehulbhai Pravinbhai Vaghela, who also serves as the proprietor of the company. Under his guidance, the company has focused on expanding its presence in the pharmaceutical export market. Specific information regarding other key executives, such as the Chief Financial Officer (CFO) or Chief Operating Officer (COO), is not publicly disclosed. The company's leadership is committed to maintaining high standards of quality and compliance in its operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Medicine House Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Medicine House's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has engaged in exporting products such as insulin, ustekinumab, and daunorubicin, with insulin being the most significant export product. Specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. The company's export activities are subject to the regulations and requirements of the importing countries, and it is essential for importers to verify the regulatory status of products before procurement.

2Emerging Markets

Medicine House has been involved in exporting pharmaceutical products to various emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's focus on finished pharmaceutical formulations allows it to cater to the growing demand for quality medicines in these regions. While specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly available, the company's adherence to international quality standards positions it to meet the requirements of diverse regulatory environments.

3Geographic Strategy

Medicine House — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Medicine House's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. Given the company's focus on finished pharmaceutical formulations, it is crucial for importers to verify the regulatory status of products intended for the U.S. market. This includes ensuring that the products comply with FDA regulations and that the manufacturing facilities are registered and inspected by the FDA.

2WHO & EU GMP

Information regarding Medicine House's WHO prequalification, EU GMP certificates, or EDQM status is not publicly available. These certifications are essential for ensuring that pharmaceutical products meet international quality standards. Importers should verify the presence of such certifications to ensure compliance with global regulatory requirements.

3CDSCO & Indian Regulatory

Medicine House operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses issued by the CDSCO, which authorize it to produce pharmaceutical products for export. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed. Importers should ensure that the products comply with the regulatory requirements of both India and the importing country.

Medicine House — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Medicine House operates in a competitive pharmaceutical export market, with numerous companies offering similar products. While specific competitors in overlapping categories are not publicly identified, the company's focus on finished pharmaceutical formulations positions it in competition with other Indian pharmaceutical exporters. The market share comparison and head-to-head analysis would require access to detailed industry reports and competitor data, which are not publicly available.

2Key Differentiators

Medicine House's key differentiators include its specialization in finished pharmaceutical formulations and its focus on specific therapeutic areas, particularly in the Diabetes & Endocrine category. The company's commitment to quality and adherence to manufacturing standards are also notable. However, the lack of diversification in its product portfolio may limit its ability to cater to a broader market segment.

3Strategic Position

Medicine House's current strategic direction appears to be focused on exporting finished pharmaceutical formulations in specific therapeutic areas. The company's future outlook would benefit from diversifying its product portfolio to mitigate risks associated with market concentration. Expanding into additional therapeutic categories and geographic regions could enhance the company's market presence and resilience.

Buyer Due Diligence Brief — Evaluating Medicine House as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Medicine House has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $634K USD across 25 shipments. The company's focus on finished pharmaceutical formulations indicates a commitment to quality and compliance with international standards. Importers should assess the reliability of the company by verifying its regulatory certifications, manufacturing practices, and product quality assurance processes.

2Certifications to Verify

Importers should verify the following certifications to ensure compliance with international standards:

FDA Registration: Confirm that the manufacturing facilities are registered with the FDA and that the products are approved for export to the U.S. market.

WHO-GMP Certification: Ensure that the manufacturing facilities adhere to Good Manufacturing Practices as outlined by the World Health Organization.

Frequently Asked Questions — Medicine House

How many pharmaceutical products does Medicine House export from India?

Medicine House exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Insulin ($571.4K), Ustekinumab ($36.9K), Daunorubicin ($26.1K). Total export value is $634.5K.

What is Medicine House's total pharmaceutical export value?

Medicine House's total pharmaceutical export value is $634.5K, based on 25 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Medicine House cover?

Medicine House exports across 3 therapeutic categories. The largest are Diabetes & Endocrine (90.1%, 1 products), Biologics & Immunotherapy (5.8%, 1 products), Advanced Oncology (4.1%, 1 products).

Get Full Medicine House Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Medicine House

Medicine House — Export Portfolio & Destination Treemap

Who is Medicine House? — Company Overview & Market Position

What Does Medicine House Export? — Product Portfolio Analysis

Top Products by Export Value

Medicine House Therapeutic Categories — 3 Specializations